Guardant Health Leads the Way in Blood-Based Single Cancer Screening
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
News Medical on MSN2h
Targeted mRNA therapy shows promise for healing damaged lungs
A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to new research from the Perelman ...
Combined organ-specific mRNA and lipid nanoparticle therapy could repair damaged lungs
A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to new research from the Perelman ...
Too Old to Operate6h
Impact of Prophylactic Cranial Irradiation in Resected Early-Stage SCLC
The following is a summary of "Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers ...